Another study reported that JIB-04 targeted imatinib-resistant chronic myeloid leukemia (CML) cells by enriching H3K36me3 on tumor suppressor gene SETD2 promoter and enhancing its transcription [74]. Here, SETD2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.